Literature DB >> 33073051

Next generation sequencing in gastric or gastroesophageal adenocarcinoma.

Geoffrey Y Ku1.   

Abstract

Seminal analyses of The Cancer Genome Atlas (TGCA) and Asian Cancer Research Group (ACRG) have provided unprecedented insight into the molecular underpinnings of gastric cancer (GC). At the same time, next generation sequencing (NGS) panels, driven by quantum improvements in DNA sequencing technology and bioinformatics, are now routinely used in standard clinical care and also extensively for research purposes. This review article will discuss the molecular subtypes of GC, the current standard-of-care therapies for GC and the role of NGS in standard care and in research. 2020 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Next generation sequencing (NGS); gastric cancer (GC); targeted therapy

Year:  2020        PMID： 33073051      PMCID： PMC7530318          DOI： 10.21037/tgh.2020.01.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


  43 in total

1.  The rising incidence of gastric cardia cancer.

Authors:  S S Devesa; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1999-05-05       Impact factor: 13.506

2.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

3.  Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Authors:  Filippo Pietrantonio; Rosalba Miceli; Alessandra Raimondi; Young Woo Kim; Won Ki Kang; Ruth E Langley; Yoon Young Choi; Kyoung-Mee Kim; Matthew Guy Nankivell; Federica Morano; Andrew Wotherspoon; Nicola Valeri; Myeong-Cherl Kook; Ji Yeong An; Heike I Grabsch; Giovanni Fucà; Sung Hoon Noh; Tae Sung Sohn; Sung Kim; Maria Di Bartolomeo; David Cunningham; Jeeyun Lee; Jae-Ho Cheong; Elizabeth Catherine Smyth
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

5.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Thorsten O Goetze; Johannes Meiler; Stefan Kasper; Hans-Georg Kopp; Frank Mayer; Georg Martin Haag; Kim Luley; Udo Lindig; Wolff Schmiegel; Michael Pohl; Jan Stoehlmacher; Gunnar Folprecht; Stephan Probst; Nicole Prasnikar; Wolfgang Fischbach; Rolf Mahlberg; Jörg Trojan; Michael Koenigsmann; Uwe M Martens; Peter Thuss-Patience; Matthias Egger; Andreas Block; Volker Heinemann; Gerald Illerhaus; Markus Moehler; Michael Schenk; Frank Kullmann; Dirk M Behringer; Michael Heike; Daniel Pink; Christian Teschendorf; Carmen Löhr; Helga Bernhard; Gunter Schuch; Volker Rethwisch; Ludwig Fischer von Weikersthal; Jörg T Hartmann; Michael Kneba; Severin Daum; Karsten Schulmann; Jörg Weniger; Sebastian Belle; Timo Gaiser; Fuat S Oduncu; Martina Güntner; Wael Hozaeel; Alexander Reichart; Elke Jäger; Thomas Kraus; Stefan Mönig; Wolf O Bechstein; Martin Schuler; Harald Schmalenberg; Ralf D Hofheinz
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

6.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Carol Colasacco; Christina B Ventura; Nofisat Ismaila; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

7.  Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.

Authors:  Yoon Young Choi; Hyunki Kim; Su-Jin Shin; Ha Yan Kim; Jinae Lee; Han-Kwang Yang; Woo Ho Kim; Young-Woo Kim; Myeong-Cherl Kook; Young Kyu Park; Hyung-Ho Kim; Hye Seung Lee; Kyung Hee Lee; Mi Jin Gu; Seung Ho Choi; SoonWon Hong; Jong Won Kim; Woo Jin Hyung; Sung Hoon Noh; Jae-Ho Cheong
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969

8.  Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Authors:  Yung-Jue Bang; Seock-Ah Im; Keun-Wook Lee; Jae Yong Cho; Eun-Kee Song; Kyung Hee Lee; Yeul Hong Kim; Joon Oh Park; Hoo Geun Chun; Dae Young Zang; Anitra Fielding; Jacqui Rowbottom; Darren Hodgson; Mark J O'Connor; Xiaolu Yin; Woo Ho Kim
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

9.  A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.

Authors:  E Van Cutsem; Y-J Bang; W Mansoor; R D Petty; Y Chao; D Cunningham; D R Ferry; N R Smith; P Frewer; J Ratnayake; P K Stockman; E Kilgour; D Landers
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

10.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962
View more
  2 in total

1.  Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter.

Authors:  Gianluca Businello; Valentina Angerilli; Sara Lonardi; Francesca Bergamo; Michele Valmasoni; Fabio Farinati; Edoardo Savarino; Gaya Spolverato; Matteo Fassan
Journal:  Updates Surg       Date:  2022-07-14

2.  Extracellular Matrix-Related Hubs Genes Have Adverse Effects on Gastric Adenocarcinoma Prognosis Based on Bioinformatics Analysis.

Authors:  Husile Alatan; Yinwei Chen; Jinghua Zhou; Li Wang
Journal:  Genes (Basel)       Date:  2021-07-20       Impact factor: 4.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.